Abstract: Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (8), formula (9), formula (10), formula (11), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

Abstract: [Problem] COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death. [Solution to Problem] Compounds represented by formulas (1) to (4) are effective when taken orally and can be expressed in smaller amounts than mangiferin.

Abstract: Provided is a novel cyclic sulfonium salt compound which is useful for the prevention or treatment of diabetes and the like. The present invention relates to a novel cyclic sulfonium salt compound represented by general formula (I) or (II), an isomer or solvate of the compound, or a pharmaceutically acceptable salt of the compound or the isomer or solvate. The present invention also relates to an ?-glucosidase inhibitor, a pharmaceutical composition for preventing or treating diabetes, and an anti-diabetes food, each of which comprises the compound represented by general formula (I) or (II) and the like.

Abstract: Provided is a novel cyclic sulfonium salt compound which is useful for the prevention or treatment of diabetes and the like. The present invention relates to a novel cyclic sulfonium salt compound represented by general formula (I) or (II), an isomer or solvate of the compound, or a pharmaceutically acceptable salt of the compound or the isomer or solvate. The present invention also relates to an ?-glucosidase inhibitor, a pharmaceutical composition for preventing or treating diabetes, and an anti-diabetes food, each of which comprises the compound represented by general formula (I) or (II) and the like.

Abstract: Disclosed are: kotalanol which has an inhibitory activity on a glucosidase; a method for producing kotalanol or a cyclic sulfonium salt which is an analogue to kotalanol by an organic synthesis technique; a cyclic sulfonium salt produced by the method; a glucosidase inhibitor comprising the compound; an anti-diabetic agent or an anti-diabetic food comprising the glucosidase inhibitor. A sulfonium compound including kotalanol can be produced by coupling a thio-sugar synthesized from D-xylose (e.g., a compound having a cyclic structure composed of 4 carbon atoms and one sulfur atom, such as 1,4-dideoxy-1,4-epithio-D-arabinitol) with a heptitol cyclic sulfate ester having a protected hydroxyl group and synthesized from a pentose (D-xylose, D-ribose, D-arabinose, D-lyxose, L-xylose, L-ribose, L-arabinose or L-lyxose) to produce a cyclic sulfonium salt having a protected hydroxyl group, and then deprotecting the hydroxyl group.

Abstract: Cyclic onium compounds reresented by the following structural formula (I), glucosidase inhibitors using such compounds, and antidiabetic drugs or food containing such glucosidase inhibitor. wherein A? is an aniom; m is an interger between 1 and 6, n is 0 or 1, X+ is S+ or N+Q (where Q is H or an alkyl of 1 to 4 carbon atoms).

Abstract: Cyclic onium compounds reresented by the following structural formula (I), glucosidase inhibitors using such compounds, and antidiabetic drugs or food containing such glucosidase inhibitor. wherein A? is an aniom; m is an interger between 1 and 6, n is 0 or 1, X+ is S+ or N+Q (where Q is H or an alkyl of 1 to 4 carbon atoms).